Cellectis Q2 2025 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: As of June 30, 2025, Cellectis reported cash, cash equivalents, and fixed-term deposits totaling $230 million, down from $264 million at the end of 2024. The decrease of $33.2 million is attributed to operational expenses, including $23.2 million to suppliers and $23.6 million in wages and bonuses.

Net Loss: Specific figures related to the consolidated net loss attributable to shareholders for the six months ended June 30, 2025, were referenced but not detailed in the call.

2Strategic Updates and Business Highlights

Clinical Trials: Cellectis is preparing to initiate a pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia (ALL) in H2 2025, following successful end-of-Phase I discussions with the FDA and EMA.

NatHaLi-01 Study: The company continues to enroll patients in the NatHaLi-01 study assessing eti-cel (UCART20x22) in non-Hodgkin lymphoma, with data expected to be presented in late 2025.

Partnerships: Ongoing R&D activities are under a collaboration with AstraZeneca, focusing on three cell and gene therapy programs.

Arbitration with Servier: Cellectis has initiated arbitration to protect its interests regarding the development of licensed CD19 products, with a decision expected by December 15, 2025.

3Forward Guidance and Outlook

R&D Day: An Investors R&D Day is scheduled for October 16, 2025, where the company will present Phase I data for lasme-cel and discuss the late-stage development strategy.

Cash Runway: The current cash position is projected to fund operations into H2 2027, including costs associated with pivotal studies for lasme-cel and eti-cel.

4Bad News, Challenges, or Points of Concern

Cash Decrease: The decline in cash reserves raises concerns about financial sustainability, particularly as the company invests in pivotal trials.

Arbitration Risks: The ongoing arbitration with Servier poses uncertainty regarding potential compensation and the future of the CD19 product line.

Market Environment: The biotech market remains challenging, which could impact funding and partnership opportunities.

5Notable Q&A Insights

Servier Arbitration: Management refrained from speculating on potential outcomes, emphasizing the complexity of the situation.

Regulatory Engagement: Positive feedback from both the FDA and EMA regarding the pivotal trial design for lasme-cel indicates a clear path forward, with no significant roadblocks anticipated.

Durability of Response: Discussions highlighted the importance of durability in response rates for UCART22, with regulatory authorities acknowledging the high unmet need in the treatment landscape.

Competitive Landscape: Cellectis remains confident in its differentiation strategy, particularly with eti-cel targeting non-CD19 antigens, amidst increasing competition from autologous CAR-T therapies. Overall, Cellectis is positioned for significant developments in the latter half of 2025, with ongoing clinical trials and strategic collaborations, despite facing financial and operational challenges.